Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D2.471 - Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children
D2.473 - Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience
D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study
D2.464 - Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid
D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients
D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab
D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case
D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study
D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey
D2.470 - Potential Clinical and Laboratory Biomarkers for Predicting Omalizumab Response in Chronic Spontaneous Urticaria
D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation
D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report
D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months
D3.140 - Transcriptomic profiling reveals distinct gene signatures and immune pathways in inhaled corticosteroid (ICS)-sensitive and resistant House Dust Mite (HDM)-induced asthma mouse models
D3.141 - Serum levels of IL-10 and IFN-GAMMA in adolescents diagnosed with asthma in clinical remission without treatment
D3.142 - Adherence to Inhaled Corticosteroid Therapy in Patients with Severe Asthma at a Danish Tertiary Care Centre
D3.143 - Immunomodulatory role of vitamin D in severe asthma: a potential biomarker of treatment response
D3.144 - Did allergic status change the quality of life in controlled severe asthma patients with triple therapy?
D3.145 - Comparative particle size and distribution from fixed dose triple dry powder inhalers
D3.146 - Attitudes and Knowledge Levels Regarding Physical Activity in Children with Asthma and Their Parents: A Comparison with Healthy Controls
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download